Document:

EX-10.4

 Exhibit 10.4 

ENGLISH TRANSLATION 

FOR INFORMATIONAL PURPOSES 
  

			
	Lease Agreement        		 O R I G I N A L
 FEES -

	concluded between        		 SELF-ASSESSMENT
 Date: 16/03/2007

Fee: €22,591.87
 Signed/Landlo

 CONTRA Liegenschaftsverwaltung GmbH 

FN 144749 t 
 Berggasse 7, 1090
Vienna 
 (hereinafter referred to also as CONTRA) 

on the one side 
 and 

Nabriva Therapeutics Forschungs GmbH 

FN 269261 y 
 Brunnerstraße
59, 1235 Vienna 
 (hereinafter also referred to as Tenant) 

on the other side 
  

	1	Preamble 

  

	1.1	CONTRA is the registered owner of the property EZ 506 Land Register 01107 Simmering, consisting of plot nos. (Gst.-Nr.) 332/4, 332/5, 335/1 and 1803/1 with the address Leberstraße 20, 1110 Vienna. On this
property there is a building together with underground car park, and the owner thereof is CONTRA. 

  

	1.2	CONTRA shall be establishing a biotechnology research centre in this building. For the renovations and conversions of the building necessary thereto, CONTRA shall be availing itself of funding from the Wiener
Wirtschaftsförderungsfonds [Vienna Business Agency (VBA)] in accordance with the Wiener Strukturverbesserungsaktion 2005 [Vienna Structural Improvement Action 2005] (municipal council decision of 17 December 2004, Pr.Z. 05580-2004 /
0001-GFW). 

  

	1.3	The Tenant declares itself to be eligible for funding according to the conditions of the fund mentioned in section 1.2 and acknowledges that CONTRA shall be obliged to pay back the funding on a pro rata basis in
the case of non-compliance with the fund guidelines by the Tenant. This would result in the loss of the rent reduction conditional upon this funding (section 4.1) with retroactive effect. The Tenant is fully informed of said funding and shall submit
the necessary applications to the Vienna Business Agency in due time. 

	1.4	The building referred to in section 1.1 was rebuilt on the basis of a building permit issued after 30 June 1953 without the aid of public funds. 

 

	2.	Lease object 

  

	2.1	CONTRA shall lease to the Tenant and the latter shall rent from CONTRA the following areas in the basement, on the 1st, 4th, 5th, 6th, 7th floor and in the attic of the biotechnological research centre, and some
outdoor facilities: 

  

	 	•	 	Office premises with a total floor space of around 998m2 

  

	 	•	 	Biology laboratory space, animal unit and biology laboratory side rooms with a total floor area of approximately 740m2 

 

	 	•	 	Chemistry laboratory space, and chemistry laboratory side rooms with a total floor area of approximately 412m2 

 

	 	•	 	Secondary areas (kitchens, sanitary rooms, passage sections and sluices inside the lease object), the areas located in the basement and the outside facilities (outside area) with a total floor area of approximately 738m2 

 In addition CONTRA shall lease to the Tenant and the latter shall rent
from CONTRA the laboratory furniture newly acquired for the laboratory space for the tenant before the lease commencement for the account of CONTRA. 

The premises specified are outlined in colour in the Basic structure - Standard floor plan (Supplement ./1) (approximate figures). The desired
room divisions and/or uses have been outlined in red in the “Nabriva” Concept (Supplement ./4). 
 The premises shall be
adapted in consideration of a construction and equipment specification to be determined by mutual agreement between the Tenant and CONTRA. 
  

	2.2	The actual area of the premises specified shall form the basis for the calculation of the main rent and operating costs. Deviations of up to 3% in the area dimensions forming the basis of these calculations
compared to the actual dimensions may be disregarded. 

  

	2.3	The Tenant may use the lease object only for the purposes of its biotechnology research and production. Any change to the intended use shall require the express written consent of CONTRA. Only the interior of the
lease object shall be leased. 

 CONTRA is aware that the research and production processes of the Tenant are very complex and
involve procedures which sometimes react extremely sensitively to external factors. CONTRA will take due consideration for these internal processes of the Tenant accordingly. 

  
 - 2 - 

	2.4	The Tenant shall without extra payment to CONTRA be entitled to affix or have a third party affix advertising inscriptions, advertising media etc. of the Tenant to the outer surfaces of the building by mutual
agreement with CONTRA. 

 The Tenant shall be obliged to bear the costs associated with the installation and maintenance of
these inscriptions, in particular the public charges to be paid in respect to this, and upon termination of the lease, shall be obliged to remove the inscriptions and advertising media at its own expense and without damaging the fabric of the
building. 
 The attachment of other announcement boards, advertising or orientation signs outside the lease object shall likewise be
undertaken by mutual agreement with CONTRA. 
 Advertisements or boards that are mounted without agreement with CONTRA can be removed by
CONTRA at the expense and risk of the Tenant. 
  

	3.	Term of the Agreement, waiver of termination 

  

	3.1	The lease shall begin upon the structural completion of the lease object in accordance with the construction schedule, which constitutes a component part of this Agreement (Annex), on the first of the month
following the contractually compliant handover and acceptance of the lease object and shall be concluded for an indefinite duration. CONTRA shall announce the time of handover to the Tenant at least three months in advance. Minor defects such that
do not prevent the contractual intended use of the lease object shall not entitle the Tenant to refuse acceptance of the lease object. CONTRA undertakes to fix minor defects within 30 days of notification. 

The handover and acceptance shall take place no later than by 14 December 2007, provided that the following preconditions are fulfilled:

  

	 	•	 	The orders for laboratory furniture (Furniture, section 36. of the construction schedule) shall be placed in due time by the Tenant in its own name and for the account of CONTRA, so that delivery can be carried out on
the request of CONTRA from mid-October 2007. The Tenant shall be responsible for the timely delivery of furniture. 

  

	 	•	 	The order for the procurement of the autoclave to be provided by the Tenant shall be placed by the Tenant in its own name and for its own account, so that the delivery can be carried out at the request of CONTRA from
mid-August 2007. The Tenant shall be responsible for the timely delivery of the autoclave. If the autoclave is not delivered on time and compliance with the handover date (14/12/2007) for the entire lease object is therefore not possible, the
contracting parties shall define in writing by mutual agreement which areas associated with the autoclave cannot be handed over by the handover date 14/12/2007). 

  
 - 3 - 

	 	•	 	The existence of such written definition shall mean that the Tenant is not responsible for the delay, the handover date (14/12/2007) and all provisions of this Agreement referring to this date shall continue to
apply only for the other parts of building and leased area not covered by this definition, and the late delivery of the autoclave shall not represent a case of application pursuant to section 7.4. 

The Tenant is interested in the earliest possible relocation of the administration of its company. CONTRA shall endeavour, regardless of the
agreed handover date, to make a part of the planned office space (administration) available at an earlier time and hand this over to Nabriva Therapeutics Research GmbH. For these office areas, this Lease Agreement shall apply mutatis mutandis from
the point of handover. CONTRA shall thus hand over a floor containing office space ahead of time, namely before 1 June 2007, if possible. The Tenant is aware that it will have to expect restrictions and impairments to its ongoing operations on
account of the building works up until the takeover of the entire lease object. For the duration of any possible restrictions and impairments, CONTRA shall grant the Tenant an appropriate rent reduction in analogous application of § 1096,
second sentence ABGB [Austrian Civil Code]. 
 The contracting parties shall be entitled to terminate the Agreement by giving six
months’ notice to 31 March, 30 June, 30 September or 31 December of each year respectively. The Landlord can terminate the Lease Agreement only for good cause within the meaning of § 30 Mietrechtsgesetz [Austrian
Tenancy Law] or dissolve the Lease Agreement only for the reasons specified in § 1118 ABGB. 
 The Tenant shall waive the exercise of
its right of termination for a period of ten years, to be counted from the date on which the Lease Agreement commenced for the entire lease object (this shall be, subject to the fulfilment of the preconditions under section 3.1, second paragraph, no
later than 1 January 2008). Nevertheless, the Tenant can terminate the Lease Agreement during that period also with effect to the aforementioned dates in compliance with the above notice periods, but no earlier than after the expiry of two
years, to be counted from the date on which the Lease Agreement has commenced for the entire lease object (this shall be, subject to the fulfilment of the preconditions under section 3.1, second paragraph, no later than 1 January 2008), if 

 

	 	•	 	the Tenant permanently ceases its business activity due to sustained economic failure; 

  

	 	•	 	the Tenant relocates its company headquarters abroad; 

  

	 	•	 	the Tenant due to transformations under company law merges with a legal person or is acquired by another legal entity or is incorporated into an existing business, whereby the company site at 1110 Vienna,
Leberstraße 20, becomes obsolete; 

  

	 	•	 	the Tenant in accordance with the provisions of section 6.2 provides a new sub-tenant, with whom a new lease agreement is concluded. 

  
 - 4 - 

 In the case of termination of the lease before the end of the termination waiver period, the
Tenant must pay CONTRA termination compensation. The termination compensation shall be 
  

	 	•	 	upon termination of the lease within the first six years of the contractual term €200.000 net and 

  

	 	•	 	upon termination of the lease from within the seventh up to and including the tenth year of the contractual term €100.000 net. 

The above amounts shall be subject to value protection by analogous application of section 4.3. 

In the case of termination of the lease before the end of the termination waiver period, the following shall apply with respect to the
laboratory furniture: 
  

	 	•	 	The Tenant shall be entitled to buy the laboratory furniture from CONTRA. The purchase price shall be calculated from the procurement costs less four per cent (amortisation) for each completed year of the Agreement. The
Tenant shall notify CONTRA at least three months before the termination date, as to whether it wishes to buy the laboratory furniture according to the above arrangement. CONTRA shall be entitled to object to this purchase within one month. If CONTRA
objects to the purchase of laboratory furniture, the furniture shall remain in the lease object without CONTRA requiring any compensation/payment for the laboratory furniture from the Tenant. 

 

	 	•	 	If the Tenant fails to make use of its purchase option pursuant to the above paragraph and laboratory furniture for this reason remains in the lease object, the Tenant shall be obliged to pay for the laboratory
furniture/pay compensation to CONTRA. This compensation shall be calculated from the procurement costs less four per cent (amortisation) for each completed year of the Agreement, less a further deduction amount, which shall be determined by
agreement between the contracting parties. If the contracting parties cannot agree on this deduction amount, an expert opinion shall be sought to determine the value of this laboratory furniture to CONTRA if it remains in the lease object. This
value shall then be used as the deduction amount. The costs for the expert opinion shall be divided equally between the contracting parties. If the contracting parties cannot agree on the who this expert should be, the selection of the expert shall
be made by the President of the Vienna Bar Association. 

  

	 	•	 	If within six months after the end of this Lease Agreement a lease agreement is successfully concluded with a sub-tenant for the laboratory space that is the subject of this Agreement, there shall be no obligation on
the part of the Tenant to pay for the laboratory furniture/compensation. In this case, CONTRA shall repay to the Tenant without delay any compensatory amount pursuant to the above paragraph that has already been paid. 

  
 - 5 - 

 The Tenant shall pay CONTRA the termination compensation and the compensatory amount for the
laboratory furniture no later than six months after the termination date. 
 If CONTRA has availed itself of a grant in the sense of section
1.3 for the lease object and, because of the premature termination of the Agreement, a refund of the grant (or part thereof) has to be made under the guidelines of the VBA, the Tenant undertakes to compensate CONTRA for the grant funds on a pro rata
basis. The level of this proportion of grant funds (and hence the amount of compensation) shall be calculated from the difference between the main rent required of the Tenant and the main rent that would have been required, if the Tenant had not
used any funding from the outset, in each case based on the entire term of the Agreement. The amount of compensation shall be limited to the amount that the VBA requires CONTRA to repay. 

The compensation amount shall be due against invoice. The Tenant and CONTRA shall mutually agree prior to the termination, the manner in which
the payment of the compensation amount for the repayment of the grant by the Tenant shall be secured. Without such an agreement, CONTRA shall be entitled to reject the termination and to demand the continuation of the lease. 

 

	3.2	The following reasons are agreed as important reasons for termination within the meaning of § 30 para. 2 line 13 MRG: 

  

	 	•	 	The Tenant changes the contractual intended use of the lease object (Section 2.3) without the express written consent of CONTRA. 

  

	 	•	 	The Tenant undertakes a transfer of the lease object in violation of the provisions of section 6.2. 

  

	 	•	 	The Tenant violates other provisions of this Agreement despite a warning, meaning that the continuation of the Agreement is unreasonable for CONTRA. 

In the event of a termination according to the foregoing provisions or the declaration of contract rescission under §1118 ABGB, the Tenant
shall be obliged to pay CONTRA termination compensation, purchase the laboratory furniture/pay compensation for this, and pay its pro rata share of the grant funds, in analogous application of the provisions of section 3.1. 

 

	4.	Rent, security deposit 

  

	4.1	The agreed rent consists of 

  

	 	•	 	The main rent base amount of €8.00/m2 net per month for office premises, laboratory premises and the other premises and areas; 

 

	 	•	 	The main rent supplement, the amount of which is dependent on the investments (renovations and conversions) made to the lease object by CONTRA: 8 % of the investment costs, divided according to office premises and
laboratory premises, shall be required for the contractual year. Per month and square metre, the supplement shall thus be one-twelfth of these respective amounts, divided by the corresponding usable area. These supplements shall not exceed (net
monthly respectively): 

  
 - 6 - 

	 	•	 	for the office space €3.20/m2, 

  

	 	•	 	for the biology laboratory space, animal unit and biology laboratory side rooms €14.00/m2, 

 

	 	•	 	for the chemistry laboratory space and the chemistry laboratory side rooms €14.00/m2, 

 

	 	•	 	for the remaining premises and areas €3.20/m2. 

According to current calculations, the required supplements will reach the aforementioned maximum amounts. Based on the current planning
status, the main rent (MR) for the office space, laboratory space and other premises and areas shall thus be (monthly net respectively): 
  

																					
	 	  	m2	 	  	MR-base
amount per
m2	 	  	MR-
supplement
per m2	 	  	MR in total
per m2	 	  	results in
MR of:	 
	 Chemistry laboratory space and chemistry laboratory side rooms:
	  	 	412	  	  	 	8,00	  	  	 	14,00	  	  	 	22,00	  	  	 	9.064,00	  
	 Additional areas:
	  	 	738	  	  	 	8,00	  	  	 	3,20	  	  	 	11,20	  	  	 	8.265,60	  
		  	  
	  
	 	  				  				  				  	  
	  
	 
	 Totals:
		 	2.888	  														 	44.787,20	  
		  	  
	  
	 	  				  				  				  	  
	  
	 

 The investment for infrastructural measures, e.g. freight lift, shall be borne by CONTRA and not charged to
the Tenant; 
  

	 	•	 	The remuneration for the laboratory furniture depending on its procurement costs: one-twelfth of eight per cent of these procurement costs shall be billed monthly net; 

 

	 	•	 	The proportion of operating costs and public charges pursuant to section 4.4; 

  

	 	•	 	Statutory value-added tax. 

 The main rent (net) shall reduce by the pro rata funding of the
Vienna Business Agency. The crediting of the funding to the main rent shall be effected according to the guidelines of the Viennese Structural Improvement Action 2005 by reducing the investment costs to be transferred to the Tenant. The reduction of
the main rent shall be carried out only if the Tenant is eligible under the Viennese Structural Improvement Action 2005. The above values do not include the reduction by said funding. 

 

	4.2	The rent shall be due for payment on the first of the month in advance in consideration of a five-day grace period and to an account to be specified by CONTRA. At the request of CONTRA, the Tenant shall grant a
collection order in order to settle the rent payments. The Tenant agrees that for costs specified in section 4.4 , monthly advance payments shall be paid against a one-off annual settlement no later than by 30 June of the following year. The
advance payment at the beginning of the Lease Agreement shall be €260 per m2 net per month. 

  
 - 7 - 

 In the case of a partial handover of the lease object to the Tenant, only the proportional rent
pursuant to section 4. that is attributable to the area already handed over shall be due for payment until the complete handover of all the areas referred to in section 2.1. In the case of partial handover of the lease object, the provisions of this
Agreement shall apply in this respect mutatis mutandis. The date on which all listed areas are handed over to the Tenant shall be used, however, to determine the beginning of the termination waiver period. 

 

	4.3	Stability of value is expressly agreed for the main rent and the payment for the laboratory furniture. The main rent and the consideration for the laboratory furniture shall be value protected using Consumer
Price Index 2005. Should this Index no longer be published, the index which corresponds most closely to this index shall apply as a basis for the value protection. The first starting basis for the value protection shall be the index number published
for the month of the commencement of the Agreement. Fluctuations of up to and including 5% shall not be taken into consideration; beyond this threshold, however, the entire change shall take effect. The index number thus taken into account for the
upward revaluation shall be the new starting basis for the calculation of the following value adjustment. 

 CONTRA shall also
be entitled to apply the rent adjustment retrospectively for past rental periods. Under no circumstances shall the failure to carry out the rent adjustment represent a waiver of the right to value adjustment per se or to appreciation amounts
accruing but not yet claimed for the past. A reduction in the main rent by application of the above provision shall be excluded. 
  

	4.4	The scope of facility management to be organised by CONTRA is at present not yet determined. Insofar as the corresponding services are not already contracted by the Tenant itself, the operating costs shall
include 

  

	 	•	 	all expenses that are necessary for the proper operation of the biotechnology research centre, or arise through the use of general parts of the biotechnological research centre; 

 

	 	•	 	the pro rata costs for heating including the cost of maintenance and repair of the heating system (heating costs); 

  

	 	•	 	at least all items referred to in §§ 21 to 25 of the Austrian Tenancy Act (MRG). 

 The
Tenant expressly consents to appropriate insurance for the whole property. Should the Tenant not make use of facilities of the property, this shall not release it from the obligation to pay the pro rata costs. The Tenant agrees that the fee for
administering the biotechnology research centre amounts to 2.5 per mille of the appropriate fire insurance for of the whole building taking into consideration the risk to be covered, at least, however, the amount which the property manager
determines in accordance with the respective guidelines for fee scales. 
 The proportion of the operating costs payable by the Tenant that
are attributable to the whole property or are not allocated to the lease object of the Tenant shall be determined by the ratio of the floor space of the lease object to the sum of floor space of all leased premises of the biotechnology research
centre. 

  
 - 8 - 

 Operating costs that are associated with the lease object of the Tenant shall be borne by the
Tenant alone. CONTRA shall be entitled to carry out the maintenance of existing or install new sub-meters (measuring devices) at the expense of the Tenant; these shall be used for allocating operating costs to the lease object of the Tenant. 

 

	4.5	The Tenant shall be responsible for all individual consumption costs on the basis of supply contracts to be concluded in its own name with the respective utility companies. Insofar as this cannot be done, these
consumption costs shall be added to the operating costs pursuant to section 4.4. In this case, CONTRA shall in the case of default of payment by the Tenant be entitled to cease supply to the lease object of the supply services in question after a
warning and the setting of a grace period of 14 days. 

  

	4.6	In the event of a delay in payment, default interest at the level of the respective statutory default interest rate for mutual entrepreneurial transactions is agreed. In the case of default in payment, CONTRA
shall be entitled, regardless of any designation made by Tenant, to credit partial payments of the Tenant against rent payments designated by the latter. The Tenant shall not be entitled to offset counter-claims against the claims of CONTRA from
this Agreement. 

  

	4.7	The Tenant shall in order to secure all claims of CONTRA in connection with this Lease Agreement provide CONTRA no later than upon handover of the lease object with an irrevocable, abstract bank guarantee issued
in favour of CONTRA on first demand without examination of the underlying legal relationship, this to be disbursed by a bank based in Austria in the amount of three months’ gross rent with a term of at least two years or, alternatively, to
provide a cash security deposit to CONTRA to be invested at the respective base interest rate and which can also be accessed in partial amounts. The Tenant shall in the event of the payment of a bank guarantee be obliged no later than three months
before the expiry of the bank guarantee to seek the extension thereof for at least another two years; failing this, CONTRA shall be entitled to draw the bank guarantee and retain the guarantee amount as a cash deposit, which shall be non-interest
bearing. The provision of the previous sentence shall apply analogously also for any extension to the extension of the bank guarantee. 

  

	5.	Use, maintenance obligation, restoration 

  

	5.1	The Tenant confirms that the condition of the lease object, which is to be prepared according to the equipment specification agreed with CONTRA, shall be one that is suitable for its purposes. 

CONTRA shall inform the Tenant of the connected values for the supply and drain lines as well as the maximum ceiling loads. These values may
not be exceeded. The Tenant waives any claim against CONTRA in relation to possible adaptations of the lease object requested by the Tenant, which go beyond the renovations and conversions evident from

  
 - 9 - 

 
Supplement ./1 and the construction and equipment specification to be agreed upon. CONTRA shall assume no liability for a particular characteristic or a particular suitability of the lease object
to a particular use, but guarantees instead that the lease object shall be prepared properly in accordance with the construction and equipment specification (Supplement ./3). 

Any regulatory requirements associated with the use of the lease object shall be fulfilled by the Tenant at its own expense. In particular, the
Tenant shall organise any necessary business premises permit at its own expense. Insofar as the contractual use of the lease object requires corresponding considerations or regulatory approvals in connection with the renovations and conversions of
the building, that are undertaken by CONTRA in connection with the establishment of the biotechnology research centre, CONTRA shall fulfil the relevant requirements and/or obtain the necessary permits (e.g. ensuring compliance with the designation
of the building in accordance with the contractual use of the lease object). 
  

	5.2	The Tenant shall accept the lease object and all the facilities and equipment therein including the cables and pipes of all types running in the walls at its own cost in the lease object in a perfect condition
and shall be responsible for carrying out all repairs, maintenance and servicing work at its own expense using certified contractors. In the case of fire, risk of explosion or other danger to life and limb, it shall by way of derogation from the
above be the responsibility of the contracting party that first becomes aware of the defectiveness to take the necessary security measures. 

If the Tenant fails to meet this obligation in spite of a written warning setting an appropriate grace period, CONTRA shall be entitled to
carry out the necessary work at the cost and risk of the Tenant. The requirement for a warning and a grace period shall cease to apply if imminent danger exists. 

The Tenant shall notify CONTRA of any material damage in and/or to the lease object or in and/or to the biotechnology research centre with
evidence thereof immediately after becoming aware of this. The Tenant shall be liable for the adverse effects of a breach of this obligation to notify. 
  

	5.3	The Tenant shall treat the lease object together with the equipment contained therein as well as the communal systems and facilities gently and with due care, and make use of the lease object, including the
communal facilities, in such way that CONTRA or third persons are not affected. The Tenant shall be responsible for ensuring that its employees, customers, contractors and visitors also comply with these obligations. 

 

	5.4	The Tenant must first obtain express written consent from CONTRA before undertaking structural changes of any kind. Upon termination of the lease, the Tenant shall at CONTRA’s choice either leave in the
lease object the structural changes undertaken and other investments that cannot be removed without damaging the building fabric without compensation or remove these; in the latter case, any damage caused to the building fabric by the Tenant must be
remedied. CONTRA’s contractual right to choose shall be exercised together with the granting of its approval of the planned structural changes by the Tenant. 

  
 - 10 - 

	5.5	After the end of the lease, the Tenant shall hand back the lease object to CONTRA in the condition in which the Tenant accepted it, taking into consideration the usual wear and tear associated with careful use,
clear of its own movables and in a clean state. Structural changes and other investments that can be removed without damage to the building fabric shall in this case be removed by the Tenant, insofar as these by agreement between the contracting
parties are not becoming the property of CONTRA without compensation. If the Tenant fails to fulfil these obligations or fails to fulfil them in due time, CONTRA can undertake the clearing and cleaning and the removal of the changes/investments at
the risk and expense of the Tenant and for this purpose gain access to the lease object, even in the absence of an execution title. 

  

	5.6	The Tenant shall under no circumstances be entitled to a compensation claim against CONTRA for investments in the lease object (e.g. structural alterations). 

 

	5.7	CONTRA shall be entitled to make improvements and structural changes of all kinds that relate to the general parts of the building or other leased premises in the building. In this context, CONTRA shall after
giving prior notice be entitled to make use of the lease object to the extent necessary. Claims of the Tenant against CONTRA in connection with this shall arise only if said improvements or structural changes would with technically and economically
justifiable expense have also been possible without recourse to the lease object. 

 With regard to the intended use as defined
in section 2.3 realised by the Tenant in the lease object, CONTRA shall in connection with said improvements and structural changes be obliged to take all measures to ensure that the property movables owned by the Tenant, in particular the
laboratory equipment, are not damaged by emissions of any kind associated with the building work or in any other way negatively affected. The same shall apply in particular with respect to compounds, experiment set-ups etc. used in the lease object.

 The Tenant must be notified of foreseeable building measures at least in sufficient time for it to be able to make appropriate
arrangements. CONTRA acknowledges that parts of the research undertaken by the Tenant may be seriously affected, damaged and even destroyed by unforeseen disturbances. 

The maintenance obligation of the Tenant pursuant to section 5.2 shall remain unaffected. CONTRA or an authorised representative of CONTRA
shall generally be entitled to enter the lease object for important reasons at any time during business hours after giving prior notice, in cases of imminent danger, even outside business hours and without prior notice. Important reasons in this
sense shall include in particular 
  

	 	•	 	the preparation and implementation of works that the Tenant is obliged to tolerate, or 

  

	 	•	 	the inspection of the lease object for the purpose of checking compliance with the provisions of this Agreement or for the purpose of preparing a subsequent lease. 

  
 - 11 - 

 The Tenant shall be responsible for ensuring that access to the lease object by CONTRA is
possible in its absence also. 
  

	5.8	The Tenant declares that it shall not derive any legal claims from temporary disruption or outages of the water, electricity, gas, lighting, heating, ventilation, air-conditioning supply and sewerage lines or
such like, unless the disruption (outage) was caused by at least the gross negligence of CONTRA and the Tenant thereby suffers a significant disturbance to its business. The Tenant must be notified of foreseeable outages at least in sufficient time
for it to be able to make appropriate arrangements. CONTRA acknowledges that parts of the research undertaken by the Tenant may be seriously affected, damaged and even destroyed by unforeseen disturbances or outages. 

 

	5.9	The Tenant must take out business liability insurance with sufficient coverage, maintain this throughout the lease term and provide evidence of this to CONTRA upon request. 

 

	5.10	The Tenant shall be responsible for ensuring the proper disposal of accumulated special waste at its own cost. Special waste includes waste that due to its nature or amount requires separate disposal and in all
cases hazardous waste within the meaning of the Abfallwirtschaftsgesetz [Austrian Waste Management Act]. In all other respects the Tenant shall be responsible for ensuring proper waste separation. The rubbish containers provided may only be used
according to regulations. 

  

	6.	Other provisions 

  

	6.1	The Tenant shall be obliged to comply with a set of house rules yet to be issued, in their respective current version, insofar as these do not contradict the provisions of this Lease Agreement. CONTRA shall be
entitled to issue or amend regulations on the use of the general parts of the building, provided these regulations do not adversely interfere with the contractual rights of the Tenant or compromise the achievement of the contractual intended use.

  

	6.2	The Tenant may not transfer its rights arising from this Agreement, based on whatever legal title, in full or part to third parties, either for free or in return for payment (e.g. sublease). This shall also apply
for a transfer by way of a possible company relationship or long-term lease agreement. The Tenant shall not be permitted to assign to third parties any rights arising from this Agreement. 

The Tenant shall, however, be entitled to sublease the lease object to a group company or transfer its rights and obligations from this Lease
Agreement to a group company, provided CONTRA does not object to such a sublease or transfer for good cause. A group company shall be any company in which the Tenant has a direct or indirect involvement of more than 25% or which has a direct or
indirect involvement of more than 25% in the Tenant’s company or which will become the legal successor of the Tenant through the sale of the company. A good cause entitling CONTRA to object shall be in particular if the group company does not
have its headquarters in Austria. The Tenant must inform CONTRA in advance of an intended sublease or contract transfer. 

  
 - 12 - 

	6.3	Amendments or supplements to this Agreement must be made in writing. This shall also apply to any deviation from this written form requirement. Verbal ancillary agreements do not exist and/or shall lose their
validity upon signature to this Agreement by all parties. 

  

	6.4	Unless the Tenant provably informs CONTRA of a different address, legal declarations to the Tenant from CONTRA may be delivered until handover of the lease object to the address stated at the top of this
Agreement; after handover these shall be delivered to the address of the lease object. 

  

	6.5	For all disputes arising from of or in connection with this Agreement, including the validity thereof, the non-exclusive jurisdiction of the competent court Vienna’s First District is agreed as the place of
jurisdiction. 

  

	6.6	Legal transaction fees triggered by this Agreement shall be borne by the Tenant. CONTRA is obliged by law to calculate the legal transaction fees itself. The contracting parties shall each bear the costs of their
own legal advice. 

  

	6.7	This Agreement shall be drawn up in two copies, one of which is intended for each contracting party. 

  

	7.	Tenant’s right of withdrawal, contractual penalties, postponement of deadlines 

  

	7.1	The Tenant shall be entitled to withdraw from this contractual relationship by written declaration setting a grace period of six weeks, if 

 

	 	•	 	CONTRA does not hand over the lease object by 14 November 2007 at the latest; 

  

	 	•	 	CONTRA does not obtain all the mandatory official permits necessary for its intended building project thatare related to the whole property or the plot; official permits relating to the Tenant’s intended use of the
lease object are not in any event included in the aforementioned permits to be obtained by CONTRA; or 

  

	 	•	 	CONTRA fails to remedy major deficiencies in the lease object - these being deficiencies which prevent the contractual intended use of the lease object - also with respect to the contractually agreed facilities within a
reasonable time following notification thereof. 

  

	7.2	The contracting parties agree that in the event that CONTRA does not offer the lease object for transfer to the Tenant as per the Agreement by 14 December 2007 at the latest, CONTRA shall pay a contractual
penalty to the Tenant, to which the provisions of ÖNORM B2110, Issue 2003-02 -01, section 5.36.1 shall apply mutatis mutandis. This contractual penalty shall be 

  
 - 13 - 

	 	•	 	€83,333.00 in the event that CONTRA offers handover of the lease object as per the Agreement to the Tenant in the period from 15 December 2007 to 7 January 2008, 

 

	 	•	 	a further €83,333.00 in the event that CONTRA offers handover of the lease object as per the Agreement to the Tenant in the period from 8 January 2008 to 30 January 2008, and 

 

	 	•	 	a further €83,333.00 in the event that CONTRA offers handover of the lease object as per the Agreement to the Tenant after 30 January 2008 or a possible contract withdrawal declared by the Tenant becomes
effective. 

 The aforementioned amounts shall be due for payment on the first day of the delay period, thus on
15 December 2007, 8 January 2008 and 31 January 2008 respectively. 
 The Parties declare themselves to be informed of the
provisions of ÖNORM [Austrian Standard] B2110, Issue 2003-02-01, section 5.36.1: According to these, the Tenant’s claim for payment of the agreed contractual penalty arises if CONTRA is not able to prove that it or its vicarious agents
have not been responsible for the delay. Evidence of any damage shall not be required. Damages in excess of the contractual penalty shall be replaced only in the case of intent or gross negligence on the part of CONTRA. The provisions of § 1336
ABGB concerning judicial discretion shall be applied. If an extension of the performance period has been agreed, the penalty agreed for the original date shall cease to apply unless otherwise agreed. 

The Tenant is aware that CONTRA shall enter a contractual penalty agreement conforming to customary practices and thus ÖNORM B2110, Issue
2003-02-01, section 5.36.1 with the professionals appointed to carry out the structural measures in the lease object and thus cannot on its part make any commitments beyond the scope of the preceding paragraphs with respect to a contractual penalty.
The agreements between CONTRA and the professionals appointed by CONTRA shall not affect this Agreement. 
  

	7.3	Upon withdrawal from the Agreement for the reasons mentioned in section 7.1 b) or c), the Tenant shall only be entitled to additional claims against CONTRA, if CONTRA is guilty of gross negligence in the reason
for the withdrawal. 

  

	7.4	Delays in the implementation of the construction schedule (Annex) for which the Tenant is responsible shall result in a corresponding postponement of all dates and deadlines mentioned in this Agreement. A delay
in the implementation of the construction schedule (Annex) for which the Tenant is responsible shall thus result in a corresponding postponement of the latest handover date (14 December 2007) and the due dates for the contractual penalty
instalments. 

  

	Annex: 	Construction schedule (attached) 

  
 - 14 - 

 Supplements: 
  

	 	•	 	Basic structure -Standard floor plan (leased areas) 

  

	 	•	 	Technical specification of the engineering firm Mahr & Partner GmbH 

  

	 	•	 	General construction and equipment specifications “Nabriva” Concept 

  

					
	Vienna, 16 March 2007				
			
	/s/ Ralf Schmid		[stamp]		
			
	for		for		
	Nabriva Therapeutics Forschungs GmbH		CONTRA Liegenschaftsverwaltung GmbH

  
 - 15 -EX-10.5

 Exhibit 10.5 

EMPLOYMENT AGREEMENT 

THIS EMPLOYMENT AGREEMENT (the “Agreement”), is made as of August 28, 2014 by and
between Nabriva Therapeutics US, Inc. (the “Company”), and Colin Broom (the “Executive”) (together, the “Parties”). 

RECITALS 

WHEREAS, the Company desires to employ the Executive as its Chief Executive Officer and as Chief Executive Officer of its group
of companies; and 
 WHEREAS, the Executive has agreed to accept such employment on the terms and conditions set forth in
this Agreement; 
 NOW, THEREFORE, In consideration of the foregoing and of the respective covenants and
agreements of the Parties herein contained, the Parties hereto agree as follows: 
 1. Term of Employment. The term of this Agreement
shall commence on August 28, 2014 (the “Effective Date”) and end on the second anniversary of the Effective Date, unless sooner terminated in accordance with the provisions of Section 7 below or extended pursuant to the
provisions herein (the “Term of Employment”). On the second anniversary of the Effective Date and on each yearly anniversary of such date thereafter, this Agreement shall automatically renew for an additional one-year term unless either
Party notifies the other in writing of such Party’s intention not to renew this Agreement not less than ninety (90) days prior to the applicable term’s expiration date (such ninety (90) day notice period constituting the
“Termination Notice Period”). 
 2. Position. During the Term of Employment, the Executive shall serve as the Chief
Executive Officer of the Company and Nabriva Therapeutics AG, working out of his home office in Pennsylvania until he establishes a business office in the state, and travelling as required by his job duties. The Executive shall also, during the Term
of Employment, serve as a member of the Managing Board of Nabriva Therapeutics AG. In connection with his service on the Managing Board, the Executive shall enter into the Board Member Agreement attached hereto as Attachment A, and shall abide by
the terms and conditions therein and in the By-Laws of the Management Board, which are attached hereto as Attachment B. 
 3. Scope of
Employment. During the Term of Employment, the Executive shall be responsible for the performance of those duties consistent with his position as Chief Executive Officer and his position on the Managing Board of Nabriva Therapeutics AG. The
Executive shall be accountable to the Supervisory Board of Nabriva Therapeutics AG (the “Board”) and shall perform and discharge faithfully, diligently, and to the best of his ability, his duties and responsibilities hereunder. The
Executive shall devote his entire business time, loyalty, attention and efforts to the business and affairs of the Company, Nabriva Therapeutics AG, and their affiliates. The Executive’s continued membership on the board of directors of NPS
Pharmaceuticals is permitted, so long as such participating does not interfere with the Executive’s duties hereunder. Membership on boards of directors of any additional companies will be permitted only with the express approval of the Board.
The Executive agrees to abide by the rules, regulations, instructions, personnel practices and policies of the Company and Nabriva Therapeutics AG and any changes therein that may be adopted from time to time by the Company and/or Nabriva
Therapeutics AG. 

 4. Compensation. As full compensation for all services rendered by the Executive to the
Company and Nabriva Therapeutics AG, and any affiliate thereof, during the Term of Employment, the Company will provide to the Executive the following: 

(a) Base Salary. The Executive shall receive a base salary at the annualized rate of $400,000 (the “Base
Salary”), paid in equal monthly installments in accordance with the Company’s regularly established payroll procedure. Such Base Salary shall be reviewed by the Company’s remuneration committee and the Board in the first quarter of
each fiscal year; any adjustment to the Executive’s Base Salary shall be retroactively effective as of the first day of such fiscal year. 

(b) Annual Discretionary Bonus. Following the end of each fiscal year and subject to the approval of the Board, the
Executive may be eligible to receive a discretionary annual retention and performance bonus of up to 35% of the Executive’s then current Base Salary (the “Maximum Bonus”), based on the Executive’s performance and the performance
of the Company and Nabriva Therapeutics AG during the applicable fiscal year, as determined by the Board in its sole discretion. Any bonus would be pro-rated for the 2014 fiscal year. 

(c) Equity Award. The Executive is further entitled to participate in the Nabriva Therapeutics AG Option Program and
shall be granted options to purchase up to 15,827 ordinary shares of Nabriva Therapeutics AG (representing 3.75% of the current fully diluted share capital of 422,056 ordinary shares). The options shall vest over a period of 4 years and in all other
respects be subject to the terms of the Nabriva Therapeutics AG Option Program. 
 (d) Vacation. The Executive shall
be eligible for up to 20 days of paid vacation per calendar year. The number of vacation days for which the Executive is eligible shall accrue at the rate of 1.67 days per month that he is employed during such calendar year. At the end of a calendar
year, the Executive may carry over to the next year any accrued but unused vacation days, but any such carried over days will be forfeited if not used by six (6) months following the end of the calendar year. 

(e) Benefits. The Executive may participate in any and all benefit programs that the Company establishes and makes
available to its employees from time to time, provided that the Executive is eligible under (and subject to all provisions of) the plan documents governing those programs. Benefits are subject to change at any time in the Company’s sole
discretion. 
 (f) Withholdings. All compensation payable to the Executive shall be subject to applicable taxes and
withholdings. 
 5. Expenses. The Executive shall be entitled to reimbursement by the Company for all reasonable business and travel
expenses incurred by him on the Company’s behalf during the course of his employment, upon the presentation by the Executive of documentation itemizing such expenditures and attaching all supporting vouchers and receipts. Reimbursement will be

  
 - 2 - 

 
made no later than 30 calendar days after the expense is substantiated (which must occur within 30 calendar days after the expense is incurred). The expenses eligible for reimbursement under this
provision may not affect the amount of such expenses eligible for reimbursement in any other taxable year, and the right to reimbursement is not subject to liquidation or exchange for another benefit. 

6. Restrictive Covenants Agreement. As a condition of his employment, the Executive shall execute the Non-Disclosure, Inventions,
Non-Competition, and Non-Solicitation Agreement provided to him contemporaneously with this Agreement. 
 7. Employment Termination.
This Agreement and the employment of the Executive shall terminate upon the occurrence of any of the following: 
 (a)
Non-renewal of the applicable term in accordance with Section 1; provided, however, that the Company may, in its sole discretion, either direct the Executive not to come into the office during the Termination Notice Period or, in lieu of all or
part of the Termination Notice Period, pay the Executive an amount equal to the Base Salary that would otherwise have been payable to him had he remained employed for the duration of the Termination Notice Period. In such instance, the termination
of the Executive shall become effective on the date set forth in a written notice of termination to be provided by the Company (the “Early Termination Date”) and the Executive shall be paid an amount equal to the Base Salary he would have
received had he remained employed by the Company between the Early Termination Date and the end of the Termination Notice Period (the “Early Termination Pay”), with payment to be made no later than the 30th day following the end of the Termination Notice Period. 
 (b) Upon the
death or “Disability” of the Executive. As used in this Agreement, the term “Disability” shall mean a physical or mental illness or disability that prevents the Executive from performing the duties of his position for a period of
more than any three consecutive months or for periods aggregating more than twenty-six weeks. The Company shall determine in good faith and in its sole discretion whether the Executive is unable to perform the services provided for herein. 

(c) At the election of the Company, with or without “Cause” (as defined below), immediately upon written notice by
the Company to the Executive. As used in this Agreement, “Cause” shall mean a finding by the Board that the Executive: 
  

	 	(i)	failed to perform (other than by reason of physical or mental illness or disability for a period of less than three consecutive months or in aggregate less than twenty-six weeks) his assigned duties diligently or
effectively or was negligent in the performance of these duties, provided that the Executive was given prior written notice of such deficiencies and was granted a reasonable opportunity of not less than thirty (30) days to correct any such
deficiencies. 

  

	 	(ii)	materially breached this Agreement; 

  

	 	(iii)	breached his Non-Disclosure, Inventions, Non-Competition, and Non-Solicitation Agreement, or any similar agreement between the Executive and the Company; 

  
 - 3 - 

	 	(iv)	engaged in willful misconduct, fraud, or embezzlement; 

  

	 	(v)	engaged in any conduct that is, or is reasonably likely to be, materially harmful to the business, interests or reputation of the Company; or 

 

	 	(vi)	was convicted of, or pleaded guilty or nolo contendere to, a misdemeanor relating to the Company, a crime involving moral turpitude, or any felony. 

8. Effect of Termination. 

(a) Termination by the Company Without Cause. If the Executive’s employment is terminated by the Company without
Cause pursuant to Section 7(c), the Executive shall be entitled to the Base Salary that has accrued and to which the Executive is entitled as of the effective date of such termination. In addition, and subject to the conditions of
Section 8(c), the Company shall, for the remainder of the applicable term of this Agreement (except as otherwise set forth in 8(b)(ii) below): (i) continue to pay to the Executive, in accordance with the Company’s regularly
established payroll procedure, his Base Salary as severance; and (ii) provided the Executive is eligible for and timely elects to continue receiving group medical insurance pursuant to the “COBRA” law, continue to pay (but in no event
longer than eighteen (18) months following the Executive’s termination date) the share of the premium for health coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage, unless
the Company’s provision of such COBRA payments will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply (collectively, the “Severance Benefits”). 

(b) All Other Terminations. If the Executive’s employment is terminated under any circumstances other than a
termination by the Company without Cause (including a termination by the Company for Cause pursuant to Section 7(c), due to the Executive’s death or Disability pursuant to Section 7(b), or by notice of non-renewal pursuant to
Section 1 and Section 7(a)), the Company’s obligations under this Agreement shall immediately cease and the Executive shall be entitled to only the Base Salary that has accrued and to which the Executive is entitled as of the
effective date of such termination, as well as any Early Termination Pay, if applicable. The Executive shall not be entitled to any other compensation or consideration, including any bonus not yet paid, that the Executive may have received had his
Term of Employment not ceased. 
 (c) Release. As a condition of the Executive’s receipt of the Severance
Benefits, the Executive must execute and deliver to the Company a severance and release of claims agreement in a form to be provided by the Company (which will include, at a minimum, a release of all releasable claims and confidentiality,
non-disparagement, and cooperation obligations) (the “Severance Agreement”), which Severance Agreement must become irrevocable within 60 days following the date of the Executive’s termination of employment (or such shorter period as
may be directed by the Company). Severance Benefits will commence in the first regular payroll beginning after the Severance Agreement becomes effective, provided that if the foregoing 60 day period would end in a calendar year

  
 - 4 - 

 
subsequent to the year in which the Executive’s employment ends, the Severance Benefits will not begin before the first payroll of the subsequent calendar year. The Executive must continue
to comply with the Non-Disclosure, Inventions, Non-Competition, and Non-Solicitation Agreement in order to be eligible to continue receiving the Severance Benefits. 

9. Absence of Restrictions. The Executive represents and warrants that he is not bound by any employment contracts, restrictive
covenants or other restrictions that prevent him from entering into employment with, or carrying out his responsibilities for, the Company, or which are in any way inconsistent with any of the terms of this Agreement. 

10. Amendments. Any amendment to this Agreement shall be made in writing and signed by the Parties hereto. 

11. Notice. Any notice delivered under this Agreement shall be deemed duly delivered three (3) business days after it is sent by
registered or certified mail, return receipt requested, postage prepaid, one (1) business day after it is sent for next-business day delivery via a reputable nationwide overnight courier service, or immediately upon hand delivery, in each case
to the address of the recipient set forth below. 
 To Executive: 

At the address set forth in the Executive’s personnel file 

To Company: 
 Nabriva
Therapeutics AG 
 Leberstrasse 20 

A-1110 Vienna 
 Austria 

Attention: Supervisory Board 
 Either Party may
change the address to which notices are to be delivered by giving notice of such change to the other Party in the manner set forth in this Section 11. 

12. Applicable Law; Jury Trial Waiver. This Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Pennsylvania (without reference to the conflict of laws provisions thereof). Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall be commenced only in a court of the
Commonwealth of Pennsylvania (or, if appropriate, a federal court located within the Commonwealth of Pennsylvania), and the Company and the Executive each consents to the jurisdiction of such a court. The Company and the Executive each hereby
irrevocably waives any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement. 

13. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of both Parties and their respective
successors and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its assets or business; provided, however, that the obligations of the Executive are personal and shall not be assigned by
him. 

  
 - 5 - 

 14. Effect of Section 409A of the Code. 

(a) Six Month Delay. If and to the extent any portion of any payment, compensation or other benefit provided to the
Executive in connection with his employment termination is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended, (the “Code) and the
Executive is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, as determined by the Company in accordance with its procedures, by which determination Executive hereby agrees that he is bound, such portion of the payment,
compensation or other benefit shall not be paid before the earlier of (i) the expiration of the six month period measured from the date of the Executive’s “separation from service” (as determined under Section 409A of the
Code) or (ii) the tenth day following the date of his death following such separation from service (the “New Payment Date”). The aggregate of any payments that otherwise would have been paid to the Executive during the period between
the date of separation from service and the New Payment Date shall be paid to him in a lump sum in the first payroll period beginning after such New Payment Date, and any remaining payments will be paid on their original schedule. 

(b) General 409A Principles. For purposes of this Agreement, a termination of employment will mean a “separation
from service” as defined in Section 409A of the Code, each amount to be paid or benefit to be provided will be construed as a separate identified payment for purposes of Section 409A of the Code, and any payments that are due within
the “short term deferral period” as defined in Section 409A of the Code or are paid in a manner covered by Treas. Reg. Section 1.409A-1(b)(9)(iii) will not be treated as deferred
compensation unless applicable law requires otherwise. Neither the Company nor the Executive will have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by
Section 409A of the Code. This Agreement is intended to comply with the provisions of Section 409A of the Code and this Agreement shall, to the extent practicable, be construed in accordance therewith. Terms defined in this Agreement will
have the meanings given such terms under Section 409A of the Code if and to the extent required to comply with Section 409A of the Code. In any event, the Company makes no representations or warranty and will have no liability to the
Executive or any other person if any provisions of or payments under this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but not to satisfy the conditions of that section. 

15. Acknowledgment. The Executive states and represents that he has had an opportunity to fully discuss and review the terms of this
Agreement with an attorney. The Executive further states and represents that he has carefully read this Agreement, understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof, and signs his name of his
own free act. 
 16. No Oral Modification, Waiver, Cancellation or Discharge. This Agreement may be amended or modified only by a
written instrument executed by both the Company and the 

  
 - 6 - 

 
Executive. No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any
one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion. 

17. Captions and Pronouns. The captions of the sections of this Agreement are for convenience of reference only and in no way define,
limit or affect the scope or substance of any section of this Agreement. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and
pronouns shall include the plural, and vice versa. 
 18. Interpretation. The Parties agree that this Agreement will be construed
without regard to any presumption or rule requiring construction or interpretation against the drafting Party. References in this Agreement to “include” or “including” should be read as though they said “without
limitation” or equivalent forms. 
 19. Severability. Each provision of this Agreement must be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this Agreement. Moreover, if a court of competent jurisdiction determines any of the provisions contained in this Agreement to be unenforceable because the provision is
excessively broad in scope, whether as to duration, activity, geographic application, subject or otherwise, it will be construed, by limiting or reducing it to the extent legally permitted, so as to be enforceable to the extent compatible with then
applicable law to achieve the intent of the Parties. 
 20. Entire Agreement. This Agreement constitutes the entire agreement between
the Parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement, including, without limitation, the Offer Letter dated August 11, 2014. 

[Signatures on Page Following] 

  
 - 7 - 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement
as of the day and year set forth above. 
  

					
	NABRIVA THERAPEUTICS US, INC.
		
	By:		 /s/ Denise Pollard-Knight

			Name:		DENISE POLLARD-KNIGHT
			Title:		CHAIRMAN
	
	EXECUTIVE:
	
	 /s/ Colin Broom

	Colin Broom

  
 - 8 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]